BIBLIOGRAPHIE

gggg

Revenir à la page d'informations médicales sur le Fibrotest : cliquez ici

  1. Imbert-Bismut F, Ratziu V, Pieroni L, Charlotte F, Benhamou Y, Poynard T. Biochemical markers of liver fibrosis in patients with hepatitis C virus infection: a prospective study. Lancet. 2001; 357: 1069-75.
  2. Poynard T, Imbert-Bismut F, Ratziu V, Chevret S, Jardel C, Moussalli J, Messous D, Degos F. Biochemical markers of liver fibrosis in patients infected by Hepatitis C Virus: Longitudinal validation in a randomized trial. J Viral Hep. 2002; 9: 128-33.
  3. Myers RP, Ratziu V, Charlotte F, Imbert-Bismut F, Poynard T. Biochemical markers of liver fibrosis: a comparison with historical features in patients with chronic hepatitis C. Am J Gastroenterol. 2002; 97: 2419-25.
  4. Halfon P, Imbert-Bismut F, Messous D, Antoniotti G, Benchetrit D, Cart-Lamy P, Delaporte G, Doutheau D, Klump T, Sala M, Thibaud D, Trepo E, Robert P. Myers RP, Poynard T. A prospective assessment of the inter-laboratory variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) in patients with chronic liver disease Comp Hep. 2002; 2: 3-7.
  5. Myers RP, de Torres M, Imbert-Bismut F, Ratziu V, Charlotte F, Poynard T. Biochemical markers of fibrosis in patients with chronic hepatitis C: a comparison with prothrombin time, platelet count and the age-platelet index. Dig Dis Sci 2003; 48: 146-53.
  6. Rossi E, Adams L, Prins A, Bulsara M, De Boer B, Garas G, MacQuillan G, Speers D, Jeffrey G. Validation of the FibroTest Biochemical Markers Score in Assessing Liver Fibrosis in Hepatitis C Patients. Clin. Chem. 2003; 49: 450-454.
  7. Corresponding previously published abstract: Adams L, Rossi E, DeBoer B, Speers D, Macquillan G, Garas G, Jeffrey G. Use of FibroTest to predict liver fibrosis in hepatitis C: a replacement for liver biopsy? Gastroenterology 2002; 122: 1615A. (Abstract)
  8. Poynard T, Imbert-Bismut F, Ratziu V, Myers RP, Di Martino V, Thabut D, Moussalli J,  Benhamou Y. FibroTest even better than liver biopsy ? Clin Chem 2003. Electronic Letter   http://www.clinchem.org/cgi/eletters/49/3/450. Response: (21 March 2003)
  9. Myers RP, Benhamou Y, Imbert-Bismut F, Thibault V, Bochet M, Charlotte F, Ratziu V, Bricaire F, Katlama C, Poynard T. Serum biochemical markers accurately predict liver fibrosis in HIV and hepatitis C virus-coinfected patients. AIDS 2003; 17: 721-25.
  10. Thabut D, Simon M, Myers RP, Messous D, Thibaut V, Imbert-Bismut F, Poynard T. Noninvasive prediction of fibrosis in patients with chronic hepatitis C. Hepatology 2003; 37: 1220-1. (Letter)
  11. Poynard T, McHutchison J, Manns M, Myers RP, Albrecht J.  Biochemical surrogate markers of liver fibrosis and activity in a randomized trial of peginterferon alfa-2b and ribavirin. Hepatology. 2003; 38: 481-92.
  12. Myers RP, Tainturier MH, Ratziu V, Piton A, Thibault V, Imbert-Bismut F, Messous D, Charlotte F, Di Martino V, Benhamou Y, Poynard T. Prediction of liver histological lesions with biochemical markers in patients with chronic hepatitis B. J Hepatol. 2003; 39: 222-30.
  13. Le Calvez S, Thabut D, Messous D, Munteanu M, Ratziu V, Imbert-Bismut F, Poynard T. FibroTest has higher Predictive values than APRI for fibrosis diagnosis in patients with chronic hepatitis C. Hepatology. 2004; 39: 862-3. (Letter)
  14. Imbert-Bismut F, Messous D, Thibaut V, Myers RB, Piton A, Thabut D, Devers L, Hainque B, Mercadier A, Poynard T. Intralaboratory analytical variability of biochemical markers of fibrosis (FibroTest) and activity (ActiTest) and reference ranges in healthy blood donors. Clin Chem Lab. Med 2004; 42: 323-33.
  15. The prediction of fibrosis with serum biochemical markers in patients with chronic hepatitis C: Prospective validation in 534 patients. Hepatology 2002; 36: 351A. (Abstract)
  16. Thabut D, Imbert-Bismut F, Cazals-Athem D, Moreau R, Messous D, Ratziu V, Munteanu M, Valla D, Lebrec D, Poynard T. Diagnostic value of fibrosis biochemical markers (FibroTest) for the prediction of portal hypertension in liver disease. Hepatology. 2003; 38: 292A. (Abstract)
  17. Thabut D, Trabut JB, Le Calvez S, Thibaut V, Massard J, d’Arondel C, Moussalli J, Munteanu M, Imbert-Bismut F, Messous D, Benhamou Y, Ratziu V, Poynard T. Diagnostic value of fibrosis biochemical markers (FibroTest) for the screening of oesophageal varices in patients with chronic liver disease. Hepatology. 2003; 38: 293A. (Abstract)
  18. Poynard T, Imbert-Bismut F, Munteanu M, Messous D, Myers RP, Thabut D, Ratziu V, Mercadier A, Benhamou Y, Hainque B. Overview of the diagnostic value of biochemical markers of liver fibrosis (FibroTest,) and necrosis (ActiTest) in patients with chronic hepatitis C. Comp Hepatol 2004; 3: 8.
  19. Naveau S, Raynard B, Ratziu V, Abella A, Imbert-Bismut F, Messous D, Beuzen F, Capron F, Thabut  D, Munteanu M, Chaput JC, Poynard T. Biomarkers for the prediction of liver fibrosis in patients with chronic alcoholic liver disease (ALD). Clin Gastroenterol Hepatol. 2005; 3: 167-74.
  20. Ratziu V, Massard J, Charlotte F, Messous D, Imbert-Bismut F, Bonyhay L, Tahiri M, Munteanu M, Thabut D, Cadranel JF, Le Bail B, De Ledinghen V, Poynard T, the LIDO Study Group and the CYTOL Study Group Diagnostic value of biochemical markers (FibroTest-FibroSURE) for the prediction of liver fibrosis in patients with non-alcoholic fa.tty liver disease. BMC Gastroenterology 2006, 6:6.
  21. Halfon P, Bourliere M, Deydier R, Portal. I, Renou R, Bertrand J, Trana A, Rosenthal A, Rotily M, Sattonet A. Independent prospective multicenter validation of biochemical markers (FibroTest-ActiTest) for the prediction of liver fibrosis and activity in patients with chronic hepatitis C. Am J Gastroenterol. 2006; 101: 547–555.
  22. Poynard T, Munteanu M, Imbert-Bismut F, Charlotte F, Thabut D, Le Calvez S, Messous D, Thibault V, Benhamou Y, Moussalli J, Ratziu V. Prospective Analysis of Discordant Results between Biochemical Markers and Biopsy in Patients with Chronic Hepatitis C. Clin Chem. 2004; 50: 1344-55.
  23. Poynard T, Yuen M, Ratziu V, Lai C. Viral hepatitis C. Lancet 2003; 362: 2095-100.
  24. Callewaert N, Van Vlierberghe H, Van Hecke A, Laroy W, Delanghe J, Contreras R. Noninvasive diagnosis of liver cirrhosis using DNA sequencer-based total serum protein glycomics. Nat. Med. 2004; 10: 1-6.
  25. Borroni G, Cazzaniga M, Ceriani R, Tommasini M, Maltempo C, FellineC, Maggi A comparison of usefulness and accuracy of simple nonivasive models as predictors of cirrhosis in chronic hepatitis C. J Hepatol. 2004; 40: 137. (Abstract)
  26. D’Arondel C, Munteanu M, Moussalli J, Thibault V, Naveau S, Simon A, Messous D, Morra R, Blot C, Poynard T. A prospective assessment of an “a la carte" regimen of PEG Interferon alfa 2b and ribavirin combination in patients with chronic hepatitis C using biochemical markers. J Vir Hep. 2006; 13: 182-9.
  27. Munteanu M, Messous D, Thabut D, Imbert-Bismut F, Jouys M, Massard J, Piton A, Bonyhay L, Ratziu V, Hainque B, Poynard T.  Intra-individual fasting versus postprandial variation of biochemical markers of liver fibrosis (FibroTest) and activity (ActiTest). Comp Hep. 2004; 23: 3.
  28. Poynard T, Imbert-Bismut F, Ratziu V. Serum Markers of Liver Fibrosis. Hepatology Rev 2004; 1: 25-33.
  29. Thabut D, Trabut JB, Massard J, Rudler M, Munteanu M, Messous D, Poynard T. Non-invasive diagnosis of large oesophageal varices with FibroTest in patients with cirrhosis: a preliminary retrospective study. Liver Int. 2006;26:271-8
  30. Sène D, Limal N, Messous D, Ghillani-Dalbin P, Charlotte F, Halfon P, Thiollière  JM, Piette J-C, Imbert-Bismut F, Poynard T, Cacoub P. Biochemical markers of liver fibrosis and activity as non invasive alternatives to liver biopsy in patients with chronic hepatitis C and mixed cryoglobulinemia vasculitis. Clin Biochem. 2006; 39: 715-21.
  31. Castéra L, Van Hecke A, Trimoulet P, Callewaert N, Couzigou P, de Lédinghen V, Contreras R, Laroy W. « Clinical glycomics »: independant validation and comparison with Fibroscan and FibroTest for the assessment of fibrosis in chronic hepatitis C. Gastroenterol Clin Biol. 2005; 29: 901.(Abstract)
  32. Sebastiani G, Vario A, Guido M, Noventa F, Plebani M, Pistis R, Ferrari A, Alberti A. Stepwise combination algorithms of non-invasive markers to diagnose significant fibrosis in chronic hepatitis C. J Hepatol. 2006; 44: 686-93.
  33. Jacqueminet S, Lebray P, Morra R, Munteanu M, Devers L,Messous D, Bernard M, Heurtier A, Imbert-Bismut F, Mercadier A, Ratziu V, Grimaldi A, Poynard T Efficacy of screening for advanced fibrosis (AF) using non-invasive biomarkers (FibroTest-FibroSURE)(FT) in diabetic patients (Db). J Hepatol 2006; 44: S260 (Abstracts)
  34. Dev A, Zekry A, Shaw L, Heller K, Patel K, McHutchison J. Independent evaluation of a serum biochemical marker panel (FibroTest) to predict fibrosis in a US cohort of chronic hepatitis C (CHC) patients. Hepatology. 2004; 40: 686A. (Abstract)
  35. Varaut A, Fontaine H, Serpaggi J, Verkarre V, Vallet-Pichard A, Nalpas B, Imbert Bismuth F, Lebray P, Pol S. Diagnostic accuracy of the FibroTest in hemodialysis and renal transplant patients with chronic hepatitis C virus. Transplantation. 2005; 80: 1550-5.
  36. De Ledinghen V, Le Bail B, Rebouissoux L, Foucher J, Castéra L, Darriet M, Lamireau T. Fibroscan, a new non-invasive method for the diagnosis of liver fibrosis in children:  prospective comparison with FibroTest- FIBROSURE™ and liver biopsy. Gastroenterol Clin Biol. 2005; 29: 899. (Abstract)
  37. Poynard T, Zoulim F, Ratziu V, Degos F, Imbert-Bismut F, Deny P, Landais P, El Hasnaou A, Slama A, Blin P, Thibault V, Parvaz P, Munteanu M, Trepo C. Longitudinal assessment of histology surrogate markers (FibroTest–ActiTest) during lamivudine therapy in patients with chronic hepatitis B infection. Am J Gastroenterol 2005; 100: 1970-80.
  38. Dev A, White I, Symonds W, Patel K, Griffin P, Tsokanas N, Skehel M, Liu C, Zekry A, Cutler P, Gattu N, Rockey D, Berrey M, McHutchison J. A Serum Proteomic Analysis in Hepatitis C Fibrosis. J Hepatol. 2005; 42: 117. (Abstract)
  39. Morra R,  Ratziu V, Bedossa P, Dargere D,  Munteanu M, Paradis V, Imbert-Bismut F, Poynard T. Diagnostic value of  biochemical markers, FibroTest-ActiTest- FIBROSURE™ (FT-AT) compared with serum protein profiling by Seldi-Tof Proteinchip (STP), for the diagnosis of bridging fibrosis in patients with chronic hepatitis C. Hepatology. 2004; 40: 517A. (Abstract)
  40. Messous D, Munteanu M, Morra R, Piton A, Poynard T, Hainque B, Imbert-Bismut F. Time impact of serum storage temperature on stability of important liver enzymes and proteins, and on FibroTest-ActiTest results. Clinica Chimica Acta.. 2005; 335: 400.
  41. Rosenthal-Allieri MA, Peritore M, Tran A, Halfon P, Benzakena S, Bernada A. Analytical variability of the FibroTest proteins. Clin Biochem. 2005; 38; 473-8.
  42. Rosenthal-Allieri MA, Tran A, Halfon P, Peritore ML, Imbert-Bismut F, Munteanu M, Messous D, Poynard T, Bernard A. Inter-technique variability of FibroTest-ActiTest proteins assays in chronic hepatitis C patients. Gastroenterol Clin Biol 2005; 29: 902. (Abstract)
  43. Imbert-Bismut F, Messous D, Raoult A, Poynard T, Bertrand JJ, Marie PA, Louis V, Audy C, Thouy JM, Hainque B, Piton A. Results transferability on RXL, ARX, X-Pand, BN2 (Dade Behring) and modular DP (Roche Diagnostics) analysers: application to component assays of FibroTest and ActiTest. Ann Biol Clin 2005; 63: 305-13.
  44. Piton A, Messous D, Imbert-Bismut F, Berges J, Munteanu M, Poynard T, Hainque B. Alpha 2 macroglobulin immunoturbidimetric assays (DakoCytomation reagents) on Roche Diagnostic analysers (Modular P, Cobas Integra). Application to FibroTest-ActiTest (FT-AT). Ann Biol Clin 2005; 63: 385-95.
  45. Munteanu M, Ratziu V, Imbert-Bismut F, Castille JM, Faruki H, Poynard T.  Precautions of use of non-invasive biochemical markers of liver injury FibroTest-ActiTest- FIBROSURE™ (FT-AT) in 32,527 patients with chronic hepatitis C. Hepatology. 2004; 40: 686A. (Abstract)
  46. Degott C, Sattonet C, Colnot N, Bonneau H, Benderitter T, Garcia T, Halfon P. The point of view of independent pathologists on the surrogate marker advantage for the treatment of patients infected by the VHC:  agreement and discordances. Gastroenterol Clin Biol 2003; 27: 762. (Abstract)
  47. Castéra L, Vergniol J, Foucher J, Le Bail B, Chanteloup E, Haaser M, Darriet M, Couzigou P, De Lédinghen V. Prospective comparison of transient elastography, FibroTest, APRI, and liver biopsy for the assessment of fibrosis in chronic hepatitis C. Gastroenterology. 2005; 128: 343-50.
  48. Castéra L, Le Bail B, Foucher J, Bernard PH, Bertet J, Darriet M, Couzigou P, De Lédinghen V. Prospective analysis of the prevalence of discordance between Fibroscan and FibroTest when used in combination as first-line assessment of fibrosis in chronic hepatitis C (CHC) patients. Hepatology. 2005; 42: 440A. (Abstract)
  49. Foucher J,  Vergniol J, Castéra L,  Le Bail B, Chanteloup E, Adhoute X, Darriet M, Bertet J, Couzigou P, de Lédinghen V. Fibrosis Evaluation in Chronic Liver Diseases: Comparison of Fibroscan® With Liver Biopsy, FibroTest®, Forns Score, Apri, Hyaluronan, Prothrombin Time, and AST/ALT Ratio. J Hepatol. 2005; 42: 78-9. (Abstract)
  50. Bourlière M, Pénaranda G, Renou C, Botta-Fridlund D, Tran A, Portal I, Lecomte L, Castellani P, Rosenthal-Allieri MA, Gerolami R, Ouzan D, Deydier R, Degott C, Halfon P. Validation and comparison of indexes for fibrosis and cirrhosis prediction in chronic hepatitis C patients: proposal for a pragmatic approach classification without liver biopsies. J V Hep. 2006; 13: 659-670.
  51. Colletta C, Smirne C, Fabris C, Toniutto P, Rapetti R, Minisini R, Pirisi M. Value of two noninvasive methods to detect progression of fibrosis among HCV carriers with normal aminotransferases. Hepatology. 2005; 42: 838-45.
  52. Bourlière M, Pénaranda G, Halfon P, Renou C, Ouzan D, Tran A, Botta-Fridlund D, Rosenthal E, Wartelle C, Delasalle P, Portal I, Castellani P, Gerolami R, Lecomte L  Validation of Hepascore for diagnosis of liver fibrosis in HCV patients and determination of a new algorithm.  J Clin Virol. 2006; 36: P363 (Abstract)
  53. Calès P, Oberti F, Michalak S, Hubert-Fouchard I, Rousselet MC, Konate A, Gallois Y, Ternisien C, Chevailler A, Lunel F. A novel panel of blood markers to assess the degree of liver fibrosis. Hepatology. 2005; 42: 1373-81.
  54. Ngo Y, Munteanu M, Messous D, Charlotte F, Imbert-Bismut F, Thabut D, Lebray P,  Thibault V, Benhamou Y, Moussalli J, Ratziu V, Poynard T. A prospective analysis of prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C (CHC). Clin Chem. 2006; 52: 1887-96.
  55. Munteanu M, Ratziu V, Imbert-Bismut F, Poynard T. FibroTest-ActiTest- FIBROSURE™ (FT-AT): The low negative predictive value of transaminases in aged patients with chronic hepatitis C (CHC). Hepatology 2003; 38: 517A. (Abstract)
  56. Thabut D, Le Calvez S, Thibault V, Massard J, Munteanu M, Di Martino V, Ratziu V, Poynard T. Hepatitis C in 6,865 Patients 65 yr or Older: A Severe and Neglected Curable Disease? Am J Gastroenterol. 2006; 101: 1260-7.
  57. Ratziu V, Giral P, Munteanu M, Messous D, Mercadier A, Bernard M, Morra R, Imbert-Bismut F, Bruckert E, Poynard T. Screening for advanced fibrosis using non-invasive biomarkers (FibroTest- FIBROSURE™) in patients consulting for hyperlipidemia. Aliment Pharmacol Ther. 2006 (Online Accepted).
  58. Poynard T, Imbert-Bismut F, Munteanu M, Ratziu V. FibroTest- FIBROSURE™: towards a universal biomarker of liver fibrosis? Expert Rev Mol Diagn 2005; 5: 15-21.
  59. Poynard, T, Halfon P, Castera L, Munteanu M, Imbert Bismut F, Ratziu V, Bourliere M, de Ledinghen V, FibroPaca study group. Prevalence of fibrosis stages is a major factor of variability when assessing the area under the ROC curves in the diagnostic evaluation of liver fibrosis markers Gastroenterol Clin Biol. 2006; 30: 1039. (Abstract)
  60. Castera L, Foucher J, Bertet J, Couzigou P, de Ledinghen V. Fibroscan and FibroTest to assess liver fibrosis in HCV with normal aminotransferases. Hepatology. 2006; 43: 373-4. (Letter)
  61. Poynard T, Munteanu M, Ngo Y, Torres M, Benhamou Y, Thabut D, Ratziu V.  Diagnostic value of FibroTest with normal serum aminotransferases. Hepatology. 2006; 43: 374-5. (Letter)
  62. Reply of the authors to the responses letters. Colletta C, Smirne C, Fabris C, Toniutto P, Pirisi M. Hepatology. 2006; 43: 375 (Letter)
  63. Ferard G, Piton A, Messous D, Imbert-Bismut F, Frairi A, Poynard T, Lessinger JM. Intermethod calibration of alanine aminotransferase (ALT) and gamma-glutamyltransferase (GGT) results: application to FibroTest and ActiTest scores. Clin Chem Lab Med. 2006; 44: 400-6.
  64. Wilson LE, Torbenson M, Astemborski J, Faruki H, Spoler C, Rai R, Mehta S, Kirk GD, Nelson K, Afdhal N, Thomas DL. Progression of liver fibrosis among injection drug users with chronic hepatitis C. Hepatology. 2006; 43: 788-95.
  65. Maor Y, Bashari D, Kenet G, Lubetsky A, Luboshitz J, Schapiro JM, Penaranda G, Bar-Meir S, Martinowitz U, Halfon P. Non-invasive biomarkers of liver fibrosis in haemophilia patients with hepatitis C: can you avoid liver biopsy? Haemophilia. 2006; 12: 372-9.
  66. Foucher J, Castera L, Bernard PH, Adhoute X, Bertet J, Couzigou P, de Ledinghen V Assessment of cirrhosis and its severity by Fibroscan and biochemical markers in alcoholic patients. J Hepatol. 2006; 44: S39. (Abstract)
  67. Mennecier D, Arvers P, Ceppa F, Corberand D, Harnois F, Mill O, Thiolet C, Burnat P, Nizou C, Farret O. Interest of FibroTest in the evaluation of the distribution of the fibrosis in a population of patients with excessive alcohol intake from the hepato-gastroenterology department. Gastroenterol Clin Biol. 2006; 30: A222. (Abstract)
  68. Castera L, Foucher J, Bernard PH, Saudo A, Bertet J, Couzigou P, de Ledinghen V Prospective comparison in Fibroscan and FibroTest in inactive hepatitis B carriers.  J  Hepatol. 2006; 44: S169. (Abstract)
  69. Hilleret MN, Faure P, Trocme C, Sturm N, Renversez JC, Morel F, Zarski JP, Leroy V Diagnostic accuracy of MP3 score compared to Hyaluronate and FibroTest for evaluating liver fibrosis in chronic hepatitis B. J Hepatol. 2006; 44: S172. (Abstract)
  70. Sebastiani G, Vario A, Noventa F, Guido M, Pistis R, Ferrari A, Alberti A Diagnostic performance of non invasive biomarkers of liver fibrosis and cirrhosis in chronic hepatitis B  J  Hepatol. 2006; 44: S176. (Abstract)
  71. Adhoute X, Foucher J, Castera L, Lovato B, Laharie D, Bertet J, Couzigou P, de Ledinghen V. Is liver stiffness mesurement useful in genetic hemochromatosis and hepatosiderosis? J Hepatol. 2006; 44: S242. (Abstract)
  72. .Castera L, Foucher J, Le Bail B, Bernard PH, Bertet J, Couzigou P, de Ledinghen V Prospective and independent validation of the Lok’s index for the prediction of cirrhosis in patients with chronic hepatitis C (CHC): comparison with Fibroscan, FibroTest and APRI. J Hepatol. 2006; 44: S86. (Abstract)
  73. de Ledinghen V,  Castera L, Foucher J, Tournan R, Bernard PH, Moisset G, Moncoucy X, Bertet J, Couzigou P Evaluation of fibrosis evolution using non-invasive methods according to sustained virological response in HCV patients. A pilot prospective controlled study. Hepatology. 2006; 44: 337A. (Abstract)
  74. de Ledinghen V, Foucher J, Castera L, Bernard PH, Salzmann M, Moisset G, Merrouche W, Couzigou P. Evaluation of fibrosis regression using non-invasive methods in very long-term follow-up of HCV responder patients. Hepatology. 2006; 44: 317A. (Abstract)
  75. Patel K, Kaita K, Yoshida E, Zeuzem S, Benhamou Y,  Torbenson M, Pulkstenis E, Subramanian M, Mchutchison J. Prospective Comparison of Two Commercial Non-invasive Fibrosis Serum Marker Panels (FibroSure and FibroSpect II) Before and During Therapy with albumin interferon alfa-2b in A Chronic HCV Genotype 1 Population. Hepatology 2006; 44:  617A. (Abstract)
  76. oynard T, Ratziu V, Charlotte F, Messous D, Munteanu M, Imbert-Bismut F, Massard J, Bonyhay L, Tahiri M, Thabut D, Cadranel JF, Le Bail B, de Ledinghen V and the LIDO Study Group and the CYTOL study group. Diagnostic value of biochemical markers (NashTest) for the prediction of non alcoholo steato hepatitis in patients with non-alcoholic fatty liver disease. BMC Gastroenterol. 2006; 6: 34.
  77. Lebensztejn DM, Skiba E, Tobolczyk J, Sobaniec-Lotowska ME, Kaczmarski M Diagnostic accuracy of serum biochemical fibrosis markers in children with chronic hepatitis B evaluated by receiver operating characteristics analysis. World J Gastroenterol 2005; 11: 7192-6.
    Revenir à la page d'informations médicales sur le Fibrotest : cliquez ici